*Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders;
†Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka; and
‡Laboratory of Clinical Pharmacokinetics and Drug Safety, Shizuoka General Hospital, Shizuoka, Japan.
Correspondence: Yoshiaki Yamamoto, PhD, Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, 886, Urushiyama, Shizuoka 420-8688, Japan (e-mail: [email protected]).
Supported in part by a grant-in-aid for Scientific Research C from Japan Society for the Promotion of Science (Grant Number; JP17K08483); grants from the Japan Research Foundation for Clinical Pharmacology; grants from the Research Foundation for Pharmaceutical Sciences; and Health and Labor Sciences Research Grants on rare and intractable diseases from the Ministry of Health, Labor, and Welfare, Japan (Grant Number; H29-nanchitou-ippan-010).
The authors declare no conflict of interest.
